Literature DB >> 2341893

Clinical and clinicopathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogs.

J C Lattimer1, L A Corwin, J Stapleton, W A Volkert, G J Ehrhardt, A R Ketring, J E Hewett, J Simon, W F Goeckeler.   

Abstract

A study was undertaken to determine the degree of acute bone marrow and vital organs injury sustained when dogs were administered doses of 153Sm-EDTMP calculated to irradiate an acute bone lesion arising from cancer metastasis to a dose considered palliative or even therapeutic (20-160 Gy). The study revealed significant (p less than 0.05) temporary depression of the bone marrow in all doses in the therapeutic (greater than 40 Gy) range. Palliative (20 Gy) doses caused significant leukocyte depression but insignificant (p greater than 0.05) depression of platelet and packed cell volumes when compared to control animals. A mild transient rise in the levels of serum alkaline phosphatase occurred immediately following radioisotope administration. All hematologic parameters had returned to normal by six weeks after the last injection of radioisotope. The study indicates potential for this compound as a safe, therapeutic radiopharmaceutical for treatment of cancer bone metastasis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2341893

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

1.  Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease.

Authors:  Oliver Sartor
Journal:  Rev Urol       Date:  2004

2.  Biospeciation, by potentiometry and computer simulation, of Sm-EDTMP, a bone tumor palliative agent.

Authors:  G Charmaine de Witt; P M May; J Webb; G Hefter
Journal:  Biometals       Date:  1996-10       Impact factor: 2.949

3.  Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases.

Authors:  John Longo; Stephen Lutz; Candice Johnstone
Journal:  Cancer Manag Res       Date:  2013-08-13       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.